MicroRNA-382 inhibits cell growth and migration in colorectal cancer by targeting SP1

Area of Science:

• Molecular Biology
• Oncology
• Gene Regulation

Background:

• MicroRNAs (miRs) are crucial regulators in cancer, acting as tumor suppressors or oncogenes.
• MIR-382 is a known tumor suppressor in some cancers, but its role in colorectal cancer (CRC) remains unclear.
• Specificity protein 1 (SP1) is overexpressed in CRC and linked to poor prognosis, with its regulation by MIR-382 uninvestigated.

Purpose of the Study:

• To investigate the role of MIR-382 in colorectal cancer (CRC).
• To determine if MIR-382 regulates the expression of Specificity protein 1 (SP1) in CRC.
• To elucidate the functional consequences of the MIR-382/SP1 interaction in CRC development.

Main Methods:

• Quantitative polymerase chain reaction (qPCR) to measure MIR-382 expression.
• Luciferase reporter assays and Western blotting to validate the MIR-382 and SP1 interaction.
• Cell counting kit-8 and wound-healing assays to assess cell proliferation and migration.

Main Results:

• MIR-382 expression was significantly downregulated in CRC tissues and cell lines.
• MIR-382 overexpression inhibited CRC cell growth and migration, while its knockdown promoted these behaviors.
• SP1 was identified as a direct target of MIR-382; MIR-382 overexpression reduced SP1 levels, and knockdown increased them.
• An inverse correlation between MIR-382 and SP1 was observed in CRC tissues.
• SP1 knockdown mimicked the tumor-suppressive effects of MIR-382 and attenuated the impact of MIR-382 inhibition.

Conclusions:

• A novel MIR-382/SP1 regulatory axis was identified in colorectal cancer.
• This axis plays a significant role in CRC progression, suggesting MIR-382's tumor-suppressive function.
• MIR-382 represents a promising therapeutic target for colorectal cancer treatment.